CIK 0001971543
MURA Mural Oncology plc
Insider trading from SEC Form 4. Last filing Dec 5, 2025.
In brief
Mural Oncology plc (MURA) has 27 SEC Form 4 filings on file from 9 insiders, the latest filed on Dec 5, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
11 open-market trades have been scored at MURA. The newest: Adam D. Cutler (Chief Financial Officer) sold $15k of stock on Nov 3, 2025, filed Nov 10, 2025, scored 10 (weak), under a 10b5-1 plan. The largest of the 11 shown: Vicki L Goodman (Chief Medical Officer) sold $51k on Feb 24, 2025, scored 15 (weak), under a 10b5-1 plan. 2 insiders sold within 14 days of each other around Nov 3, 2025.
10 Form 144 notices of planned sales are on file, the latest filed Nov 10, 2025.
Last 90 days
Signals
Open-market buys and sells at Mural Oncology plc, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 10Weak | Adam D. Cutler Chief Financial Officer sell | $15k 7,148 shares | -7% | - | |
| 3Weak | Vicki L Goodman Chief Medical Officer sell | $10k 5,036 shares | -6% | - | |
| 0Weak | Maiken Keson-Brookes See Remarks sell | $6,379 2,572 shares | -4% | - | |
| 3Weak | Maiken Keson-Brookes See Remarks sell | $5,352 2,158 shares | -3% | - | |
| 18Weak | Caroline Loew Chief Executive Officer sell | $30k 12,531 shares | -4% | - | |
| 3Weak | Maiken Keson-Brookes See Remarks sell | $9,308 2,731 shares | -4% | - | |
| 15Weak | Vicki L Goodman Chief Medical Officer sell | $51k 13,186 shares | -19% | - | |
| 3Weak | Maiken Keson-Brookes See Remarks sell | $8,355 2,555 shares | -6% | - | |
| 13Weak | Caroline Loew Chief Executive Officer sell | $9,394 2,763 shares | -1% | - | |
| 3Weak | Vicki L Goodman Chief Medical Officer sell | $17k 5,069 shares | -7% | - | |
| 15Weak | Adam D. Cutler Chief Financial Officer sell | $25k 7,421 shares | -9% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Nov 10, 2025 | Cutler Adam D. Officer | 7,148 0.04% of outstanding | $15k | Nov 3, 2025 | none |
| Nov 10, 2025 | Goodman Vicki L Officer | 5,036 0.03% of outstanding | $10k | Nov 10, 2025 | none |
| Jul 22, 2025 | Maiken Keson-Brookes CLO | 2,572 0.01% of outstanding | $6,404 | Jul 22, 2025 | none |
| Jul 9, 2025 | Loew Caroline Officer, Director | 12,513 0.07% of outstanding | $30k | Jul 7, 2025 | none |
| Mar 5, 2025 | Maiken Keson-Brookes CLO | 1,469 0.01% of outstanding | $5,039 | Mar 5, 2025 | $8,347 |
| Mar 5, 2025 | Loew Caroline Officer, Director | 4,313 0.03% of outstanding | $14k | Mar 4, 2025 | $9,395 |
| Feb 24, 2025 | Vicki Goodman Officer | 13,186 0.08% of outstanding | $53k | Feb 24, 2025 | none |
| Dec 23, 2024 | Maiken Keson-Brookes CLO | 2,555 0.01% of outstanding | $8,304 | Dec 23, 2024 | none |
| Nov 8, 2024 | Goodman Vicki L Officer | 5,069 0.03% of outstanding | $17k | Nov 7, 2024 | none |
| Nov 1, 2024 | Cutler Adam D. Officer | 7,421 0.04% of outstanding | $25k | Oct 31, 2024 | none |
Transactions
Every row filed, 50 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 5, 2025 | Francis M Cuss director | DDisposition to issuer Stock Option (right to buy)derivative | -8,637 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | Caroline Loew Chief Executive Officer | DDisposition to issuer Ordinary Shares | -293,059 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | Vicki L Goodman Chief Medical Officer | DDisposition to issuer Ordinary Shares | -84,727 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | George Golumbeski director | DDisposition to issuer Stock Option (right to buy)derivative | -8,637 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | Sachiyo Minegishi director | DDisposition to issuer Stock Option (right to buy)derivative | -8,637 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | Benjamin Hickey director | DDisposition to issuer Stock Option (right to buy)derivative | -8,637 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | Adam D. Cutler Chief Financial Officer | DDisposition to issuer Ordinary Shares | -99,290 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | Maiken Keson-Brookes Chief Legal Officer | DDisposition to issuer Ordinary Shares | -68,834 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | Scott Thomas Jackson director | DDisposition to issuer Stock Option (right to buy)derivative | -8,637 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | George Golumbeski director | DDisposition to issuer Stock Option (right to buy)derivative | -15,334 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | Adam D. Cutler Chief Financial Officer | DDisposition to issuer Stock Option (right to buy)derivative | -146,452 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | Maiken Keson-Brookes Chief Legal Officer | DDisposition to issuer Stock Option (right to buy)derivative | -54,242 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | Scott Thomas Jackson director | DDisposition to issuer Stock Option (right to buy)derivative | -8,462 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | Benjamin Hickey director | DDisposition to issuer Stock Option (right to buy)derivative | -8,462 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | Caroline Loew Chief Executive Officer | DDisposition to issuer Stock Option (right to buy)derivative | -379,690 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | Vicki L Goodman Chief Medical Officer | DDisposition to issuer Stock Option (right to buy)derivative | -135,604 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | Francis M Cuss director | DDisposition to issuer Stock Option (right to buy)derivative | -8,462 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | Sachiyo Minegishi director | DDisposition to issuer Stock Option (right to buy)derivative | -15,335 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | Scott Thomas Jackson director | DDisposition to issuer Stock Option (right to buy)derivative | -15,021 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | Maiken Keson-Brookes Chief Legal Officer | DDisposition to issuer Stock Option (right to buy)derivative | -31,200 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | Adam D. Cutler Chief Financial Officer | DDisposition to issuer Stock Option (right to buy)derivative | -65,000 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | Vicki L Goodman Chief Medical Officer | DDisposition to issuer Stock Option (right to buy)derivative | -65,000 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | Francis M Cuss director | DDisposition to issuer Stock Option (right to buy)derivative | -15,021 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | Caroline Loew Chief Executive Officer | DDisposition to issuer Stock Option (right to buy)derivative | -90,025 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | Benjamin Hickey director | DDisposition to issuer Stock Option (right to buy)derivative | -15,021 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | Maiken Keson-Brookes Chief Legal Officer | DDisposition to issuer Stock Option (right to buy)derivative | -65,000 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | Caroline Loew Chief Executive Officer | DDisposition to issuer Stock Option (right to buy)derivative | -134,225 | - | - | 0 | Dec 5, 2025 |
| Nov 10, 2025 | Vicki L Goodman Chief Medical Officer | SOpen-market sale Ordinary Shares10b5-1 | -5,036 | $2.08 | $10k | 84,727 | Nov 10, 2025 |
| Nov 3, 2025 | Adam D. Cutler Chief Financial Officer | SOpen-market sale Ordinary Shares10b5-1 | -7,148 | $2.09 | $15k | 99,290 | Nov 10, 2025 |
| Jul 22, 2025 | Maiken Keson-Brookes See Remarks | SOpen-market sale Ordinary Shares10b5-1 | -2,572 | $2.48 | $6,379 | 68,834 | Jul 23, 2025 |
| Jul 18, 2025 | Maiken Keson-Brookes See Remarks | SOpen-market sale Ordinary Shares10b5-1 | -2,158 | $2.48 | $5,352 | 71,406 | Jul 22, 2025 |
| Jul 7, 2025 | Caroline Loew Chief Executive Officer | SOpen-market sale Ordinary Shares10b5-1 | -12,531 | $2.43 | $30k | 293,059 | Jul 9, 2025 |
| Jun 11, 2025 | Francis M Cuss director | AGrant or award Stock Option (right to buy)derivative | +8,637 | $0.00 | $0 | 8,637 | Jun 13, 2025 |
| Jun 11, 2025 | George Golumbeski director | AGrant or award Stock Option (right to buy)derivative | +8,637 | $0.00 | $0 | 8,637 | Jun 13, 2025 |
| Jun 11, 2025 | Benjamin Hickey director | AGrant or award Stock Option (right to buy)derivative | +8,637 | $0.00 | $0 | 8,637 | Jun 13, 2025 |
| Jun 11, 2025 | Scott Thomas Jackson director | AGrant or award Stock Option (right to buy)derivative | +8,637 | $0.00 | $0 | 8,637 | Jun 13, 2025 |
| Jun 11, 2025 | Sachiyo Minegishi director | AGrant or award Stock Option (right to buy)derivative | +8,637 | $0.00 | $0 | 8,637 | Jun 13, 2025 |
| Mar 3, 2025 | Adam D. Cutler Chief Financial Officer | AGrant or award Ordinary Shares | +35,000 | $0.00 | $0 | 106,438 | Mar 5, 2025 |
| Mar 3, 2025 | Vicki L Goodman Chief Medical Officer | AGrant or award Ordinary Shares | +35,000 | $0.00 | $0 | 89,763 | Mar 5, 2025 |
| Mar 3, 2025 | Maiken Keson-Brookes See Remarks | AGrant or award Ordinary Shares10b5-1 | +35,000 | $0.00 | $0 | 76,295 | Mar 5, 2025 |
| Mar 4, 2025 | Maiken Keson-Brookes See Remarks | SOpen-market sale Ordinary Shares10b5-1 | -1,262 | $3.36 | $4,240 | 75,033 | Mar 5, 2025 |
| Mar 3, 2025 | Adam D. Cutler Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +65,000 | $0.00 | $0 | 65,000 | Mar 5, 2025 |
| Mar 3, 2025 | Vicki L Goodman Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +65,000 | $0.00 | $0 | 65,000 | Mar 5, 2025 |
| Mar 5, 2025 | Maiken Keson-Brookes See Remarks | SOpen-market sale Ordinary Shares10b5-1 | -1,469 | $3.45 | $5,068 | 73,564 | Mar 5, 2025 |
| Mar 3, 2025 | Maiken Keson-Brookes See Remarks | AGrant or award Stock Option (right to buy)derivative10b5-1 | +65,000 | $0.00 | $0 | 65,000 | Mar 5, 2025 |
| Feb 24, 2025 | Vicki L Goodman Chief Medical Officer | SOpen-market sale Ordinary Shares10b5-1 | -13,186 | $3.89 | $51k | 54,763 | Feb 25, 2025 |
| Dec 23, 2024 | Maiken Keson-Brookes See Remarks | SOpen-market sale Ordinary Shares10b5-1 | -2,555 | $3.27 | $8,355 | 41,295 | Dec 26, 2024 |
| Dec 17, 2024 | Caroline Loew Chief Executive Officer | SOpen-market sale Ordinary Shares10b5-1 | -2,763 | $3.40 | $9,394 | 237,628 | Dec 18, 2024 |
| Nov 7, 2024 | Vicki L Goodman Chief Medical Officer | SOpen-market sale Ordinary Shares10b5-1 | -5,069 | $3.33 | $17k | 67,949 | Nov 8, 2024 |
| Oct 31, 2024 | Adam D. Cutler Chief Financial Officer | SOpen-market sale Ordinary Shares10b5-1 | -7,421 | $3.41 | $25k | 71,438 | Nov 1, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Francis M Cussdirector
- Adam D. CutlerChief Financial Officer
- George Golumbeskidirector
- Vicki L GoodmanChief Medical Officer
- Benjamin Hickeypresident, officer, director
- Scott Thomas Jacksondirector
- Maiken Keson-BrookesChief Legal Officer
- Caroline LoewChief Executive Officer
- Sachiyo Minegishidirector
Questions about MURA
Answered from the filings on this page, as of the latest one.
Are insiders buying MURA?
No. In the last 90 days no insider at Mural Oncology plc bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade MURA on the open market?
Adam D. Cutler (Chief Financial Officer) sold $15k of MURA on Nov 3, 2025 and filed the Form 4 on Nov 10, 2025. InsiderTell scored 10 (weak), under a 10b5-1 plan, with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at Mural Oncology plc?
9 people have filed a Form 4 at Mural Oncology plc, among them Francis M Cuss (director), Adam D. Cutler (Chief Financial Officer), George Golumbeski (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.